AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

AZN.UK

12,598

+1.32%↑

GSK

1,620

-1.7%↓

HLN.UK

331.8

+0.58%↑

STJ

1,293

+0.58%↑

HIK

1,841

+0.82%↑

Home・Aktien・PureTech Health Plc

PureTech Health Plc

Open

141.4 0.28

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

137.2

Max

142.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	70M
Verkäufe	4M
KGV Branchendurchschnitt	9.969 35.739
EPS	-0.19
Gewinnspanne	1,727.216
Angestellte	56
EBITDA	102M

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	313M
Vorheriger Eröffnungskurs	141.12
Vorheriger Schlusskurs	141.4

PureTech Health Plc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Okt. 2025, 23:30 UTC

Heiße Aktien

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2. Okt. 2025, 21:21 UTC

Ergebnisse

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3. Okt. 2025, 00:00 UTC

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2. Okt. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2. Okt. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2. Okt. 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2. Okt. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Scales's JV Buyout Lauded by Bull -- Market Talk

2. Okt. 2025, 22:54 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Forex and Fixed Income Roundup: Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2. Okt. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Okt. 2025, 21:17 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2. Okt. 2025, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

2. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Okt. 2025, 20:49 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2. Okt. 2025, 20:00 UTC

Akquisitionen, Fusionen, Übernahmen

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2. Okt. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2. Okt. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2. Okt. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2. Okt. 2025, 18:44 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2. Okt. 2025, 18:43 UTC

Akquisitionen, Fusionen, Übernahmen

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer-Vergleich

Kursveränderung

PureTech Health Plc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für PureTech Health Plc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.